Plain-English translation of NCT06734013 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
After a liver transplant, sometimes the body's immune system attacks the new organ—a condition called rejection. This study is looking at gene patterns in liver biopsy samples to help doctors detect rejection earlier and more precisely. By identifying specific genetic markers, researchers hope to catch rejection before major symptoms appear, so treatment can start sooner.
Currently, doctors rely on standard biopsies and clinical observation to diagnose rejection, which can miss early warning signs. This study exists to develop a faster, more accurate genetic test that could spot rejection at its earliest stages—before it causes serious damage—and help doctors choose the best treatment plan for each patient.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will participate in a single study visit as part of your normal transplant care. Your doctor will perform or have already performed a liver biopsy (a small tissue sample). The researchers will analyze the genes in your biopsy sample using a specialized test to look for rejection markers. Your clinical information will be collected in a confidential, coded form. The entire process fits into your routine transplant follow-up—no extra visits or procedures beyond what you'd normally have.
AI-generated summary from trial data · Aug 19, 2026 · Not medical advice
Italy
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Enrollment target
~40 participants
Started
October 2024
Primary completion
May 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Deborah Malvi, MD
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.